FDA Approves Wearable Infusion Device To Quell Advanced Parkinson’s Disease Symptoms

On February 4, 2025, the U.S. Food and Drug Administration (FDA) approved a wearable, subcutaneous infusion device called Onapgo that provides continuous treatment with apomorphine during the waking day to provide more consistent symptom control for people with advanced Parkinson’s disease. The approval was based on the outcomes of a clinical trial that compared Onapgo with a placebo. Those assigned to the Onapgo group had more hours without Parkinson’s movement symptoms and were more likely to report general health improvements.

The device was developed by Supernus Pharmaceuticals, Inc. The company plans to launch Onapgo commercially in the . . .